Hypoxia is the primary cause of numerous diseases, such as covid-19, asthma, chronic obstructive pulmonary disease, and pneumonia. Hypoxemia is a condition characterized by insufficient tissue oxygen levels.
Patients commonly suffer from shortness of breath, fatigue, headaches, and vertigo. Oxygen therapy is used to treat hypoxia. Oxygen is administered through a respirator or tubing. In a few instances, mechanical ventilation provides oxygen and enhances respiration. The oxygen provider is responsible for monitoring the patient's response and ensuring that the patient's oxygen saturation levels are within the target range.
As the market evolves, the rising prevalence of hypoxia-related conditions, the expansion of clinical trials, the ongoing development of technology, the escalating demand from consumers, and the growth of FDA approvals will likely boost the hypoxia treatment market.
The global hypoxia treatment market reached US$ 77.6 million in 2022 and is expected to reach US$ 134.3 million by 2030 growing with a CAGR of 7.2% during the forecast period 2023-2030.
In recent years, the hypoxia treatment market has witnessed a series of product launches and approvals contributing to its growth. DataM Intelligence's in-depth market analysis reveals the major market drivers, challenges, and trends.
Our market intelligence report evaluates the market size, growth, and share, providing crucial insights for businesses to make informed decisions and capitalize on the existing and upcoming opportunities in the hypoxia treatment market.
The most recent DataM Intelligence report expected that the rising prevalence of hypoxia and improvements in healthcare infrastructure drive the market revenue growth or the major market trends. The global " Hypoxia Treatment market" will expand at a significant CAGR of 7.2% by 2030.
Hypoxia Treatment Market Drivers:
Expected to Grow Due to an Increase in Clinical Trials for Hypoxia Conditions:
Capital Medical University performed a clinical trial on an exploratory investigation of intermittent hypoxia therapy in chronic cerebral hypoperfusion on April 25, 2023, according to ClinicalTrials.gov. In this interventional trial, individuals with chronic cerebral hypoperfusion will be treated with intermittent hypoxia to determine its safety and effectiveness.
In order to preliminary investigate the safety and possible efficacy of intermittent hypoxia therapy in chronic cerebral hypoperfusion, this research is an exploratory study that combines intermittent hypoxia treatment with chronic cerebral hypoperfusion.
In addition, Shanghai East Hospital conducted an interventional trial using UC-MSCs on January 18, 2023, to treat patients with severe and serious COVID-19 who had refractory hypoxia.
The primary goal of the study is to evaluate the effectiveness and safety of umbilical cord mesenchymal stem cells (UC-MSCs) in the treatment of severe and critical COVID-19 patients who have persistent hypoxia despite receiving adequate standard care, as per the tenth edition of Chinese guidelines for COVID-19 infection. The market is thus anticipated to grow throughout the projected period due to the aforementioned reasons.
Hypoxia Treatment Market Restraining Factors:
- Lack of disease awareness in remote and neglected regions is expected to hinder the market's revenue growth.
- In addition, high costs associated with research and development capabilities and a scarcity of qualified professionals will restrain the market's revenue growth.
- Strict government laws and regulatory policies are also anticipated to limit market revenue growth.
Hypoxia Treatment Market Opportunities:
- Some of the factors providing future growth opportunities for major players in the hypoxia market include rising demand for target mode therapies, increased focus on strategic initiatives by market players, a surge in research and development activities for the development of novel drugs and therapies, and increased spending for the development of healthcare infrastructure.
- The growing corpus of research on cardiovascular disorders and ongoing improvements in cancer treatment are key themes pushing new technological innovations in the hypoxia industry.
Key Market Trends and Innovation:
- According to studies, years-long hypoxia of cells in the body is believed to be the primary cause of cancer. Hypoxia-activated prodrugs and specific targeting of HIFs, as well as targeting hypoxic cell-relevant pathways such as the mTOR and UPR pathways, have been proposed as strategies for targeting hypoxic tumor cells.
- In August 2021, the FDA approved Merck's WELIREGTM (belzutifan), a Hypoxia-Inducible Factor-2 Alpha (HIF-2) Inhibitor, for the treatment of patients with certain forms of malignancies associated with Von Hippel-Lindau (VHL) disease.
Market Key Players:
The global hypoxia treatment market is fairly fragmented, with many large and medium-sized players accounting for most of the market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, and developing, testing, and introducing more effective hypoxia treatment solutions.
The major global players in the market include:
- CASI Pharmaceuticals Inc.
- Aileron Therapeutics, Inc.
- Lupin Pharmaceuticals, Inc.
- PharmaShots
- Hancock Medical Inc.
- Hamilton Company
- Spotlight Labs
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Merck & Co.
To Know More Download Sample
